Polyrizon

Polyrizon SG&A Expenses

The Selling, General & Administrative Expenses of Polyrizon (PLRZ) as of Nov 20, 2026 is 3.65 M USD. In the previous year, Selling, General & Administrative Expenses was 768,000.00 USD — a change of 375.52% (higher).

SG&A Expenses

3.65 MUSD

YoY

375.52%

Last updated:

Selling, General & Administrative Expenses of Polyrizon is 2025 3.65 M USD. Selling, General & Administrative Expenses of Polyrizon was 2024 768,000.00 USD. It decreases by 375.52% higher compared to the previous year.

The Polyrizon SG&A Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

SG&A Expenses
Date
SG&A Expenses
Jan 1, 2020
33,000.00 USD
Jan 1, 2021
452,000.00 USD
Jan 1, 2022
533,000.00 USD
Jan 1, 2023
303,000.00 USD
Jan 1, 2024
768,000.00 USD
Jan 1, 2025
3.65 M USD
The Polyrizon SG&A Expenses history
YEARSG&A ExpensesYoY
3.65 MUSD+375.52%
768,000.00USD+153.47%
303,000.00USD-43.15%
533,000.00USD+17.92%
452,000.00USD+1,269.70%
33,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon Stock analysis

What does Polyrizon do? Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements. Polyrizon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Polyrizon stock

Selling, General & Administrative Expenses of Polyrizon is 3.65 M USD in 2025.

Selling, General & Administrative Expenses of Polyrizon changed from 768,000.00 USD to 3.65 M USD, representing a 375.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Selling, General & Administrative Expenses Polyrizon since 2006 – with annual values, charts, and detailed analysis.

SG&A expenses include all non-production costs such as salaries, marketing, rent, and administrative overhead. They are a key component of operating expenses.

Selling, General & Administrative Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Selling, General & Administrative Expenses's Polyrizon historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Polyrizon

All Key Metrics — Polyrizon